KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Work In Process (2021 - 2025)

Historic Work In Process for Bionano Genomics (BNGO) over the last 5 years, with Q3 2025 value amounting to $388000.0.

  • Bionano Genomics' Work In Process fell 8917.11% to $388000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $388000.0, marking a year-over-year decrease of 8917.11%. This contributed to the annual value of $2.3 million for FY2024, which is 7600.61% down from last year.
  • Bionano Genomics' Work In Process amounted to $388000.0 in Q3 2025, which was down 8917.11% from $653000.0 recorded in Q2 2025.
  • Bionano Genomics' 5-year Work In Process high stood at $10.6 million for Q2 2023, and its period low was $388000.0 during Q3 2025.
  • In the last 5 years, Bionano Genomics' Work In Process had a median value of $5.8 million in 2022 and averaged $5.6 million.
  • Its Work In Process has fluctuated over the past 5 years, first surged by 32500.0% in 2022, then tumbled by 8917.11% in 2025.
  • Bionano Genomics' Work In Process (Quarter) stood at $1.7 million in 2021, then surged by 325.0% to $7.1 million in 2022, then skyrocketed by 38.77% to $9.8 million in 2023, then tumbled by 76.01% to $2.3 million in 2024, then tumbled by 83.48% to $388000.0 in 2025.
  • Its last three reported values are $388000.0 in Q3 2025, $653000.0 for Q2 2025, and $1.6 million during Q1 2025.